Skip to main content

Advertisement

SpringerLink
Log in

The combination of stem cell markers CD133 and ABCG2 predicts relapse in stage I non-small cell lung carcinomas

  • Original Paper
  • Published:
Medical Oncology Aims and scope Submit manuscript

Abstract

The aim of the study was to investigate the expression of two cancer stem cell markers CD133 and ATP-binding cassette superfamily G member 2 (ABCG2) in non-small cell lung carcinomas (NSCLC) and evaluate their prognostic values for postoperative relapse. The expression levels of CD133 and ABCG2 in 145 stage I NSCLC tumors were detected by immunohistochemistry. Positive CD133 and ABCG2 expression was defined in 31.7 and 37.9% of the NSCLC tumors, respectively. Both stem markers alone did not correlate with any of the clinicopathological characteristics and were insufficient to predict recurrence after surgery. However, our results showed that the dual expression of CD133 and ABCG2 (CD133+/ABCG2+) status was an independent predictor of postoperative recurrence for patients with stage I NSCLC. Furthermore, CD133+/ABCG2+ NSCLC tumors (33 cases, 22.8%) had a significantly higher microvessel density and higher expression levels of angiogenic factors than the other subgroups. In conclusion, this study suggests that NSCLC patients with the dual expression of CD133 and ABCG2 have a high risk of early relapse and might benefit from anti-angiogenesis therapy.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Lau CL, Harpole DH Jr, Patz E. Staging techniques for lung cancer. Chest Surg Clin N Am. 2000;10:781–801.

    PubMed  CAS  Google Scholar 

  2. Kitamura H, Okudela K, Yazawa T, Sato H, Shimoyamada H. Cancer stem cell: implications in cancer biology and therapy with special reference to lung cancer. Lung Cancer. 2009;66:275–81.

    Article  PubMed  Google Scholar 

  3. Salnikov AV, Gladkich J, Moldenhauer G, Volm M, Mattern J, Herr I. CD133 is indicative for a resistance phenotype but does not represent a prognostic marker for survival of non-small cell lung cancer patients. Int J Cancer. 2010;126:950–8.

    PubMed  CAS  Google Scholar 

  4. Jiang T, Collins BJ, Jin N, Watkins DN, Brock MV, Matsui W, et al. Achaete-scute complex homologue 1 regulates tumor-initiating capacity in human small cell lung cancer. Cancer Res. 2009;69:845–54.

    Article  PubMed  CAS  Google Scholar 

  5. Ma S, Chan KW, Hu L, Lee TK, Wo JY, Ng IO, et al. Identification and characterization of tumorigenic liver cancer stem/progenitor cells. Gastroenterology. 2007;132:2542–56.

    Article  PubMed  CAS  Google Scholar 

  6. Zeppernick F, Ahmadi R, Campos B, Dictus C, Helmke BM, Becker N, et al. Stem cell marker CD133 affects clinical outcome in glioma patients. Clin Cancer Res. 2008;14:123–9.

    Article  PubMed  CAS  Google Scholar 

  7. Yoh K, Ishii G, Yokose T, Minegishi Y, Tsuta K, Goto K, et al. Breast cancer resistance protein impacts clinical outcome in platinum-based chemotherapy for advanced non-small cell lung cancer. Clin Cancer Res. 2004;10:1691–7.

    Article  PubMed  CAS  Google Scholar 

  8. Lee TK, Poon RT, Yuen AP, Ling MT, Wang XH, Wong YC, et al. Regulation of angiogenesis by Id-1 through hypoxia-inducible factor-1alpha-mediated vascular endothelial growth factor up-regulation in hepatocellular carcinoma. Clin Cancer Res. 2006;12:6910–9.

    Article  PubMed  CAS  Google Scholar 

  9. Zhou J, Tang ZY, Fan J, Wu ZQ, Ji Y, Xiao YS, et al. Capecitabine inhibits postoperative recurrence and metastasis after liver cancer resection in nude mice with relation to the expression of platelet-derived endothelial cell growth factor. Clin Cancer Res. 2003;9:6030–7.

    PubMed  CAS  Google Scholar 

  10. Yamashita T, Forgues M, Wang W, Kim JW, Ye Q, Jia H, et al. EpCAM and alpha-fetoprotein expression defines novel prognostic subtypes of hepatocellular carcinoma. Cancer Res. 2008;68:1451–61.

    Article  PubMed  CAS  Google Scholar 

  11. Sun HC, Tang ZY, Li XM, Zhou YN, Sun BR, Ma ZC. Microvessel density of hepatocellular carcinoma: its relationship with prognosis. J Cancer Res Clin Oncol. 1999;125:419–26.

    Article  PubMed  CAS  Google Scholar 

  12. Zhang M, Song T, Yang L, Chen R, Wu L, Yang Z, et al. Nestin and CD133: valuable stem cell-specific markers for determining clinical outcome of glioma patients. J Exp Clin Cancer Res. 2008;27:85.

    Article  PubMed  CAS  Google Scholar 

  13. Shan YF, Huang YL, Xie YK, Tan YH, Chen BC, Zhou MT, et al. Angiogenesis and clinicopathologic characteristics in different hepatocellular carcinoma subtypes defined by EpCAM and alpha-fetoprotein expression status. Med Oncol 23 Jun 2010. [Epub ahead of print].

  14. Karoubi G, Gugger M, Schmid R, Dutly A. OCT4 expression in human non-small cell lung cancer: implications for therapeutic intervention. Interact Cardiovasc Thorac Surg. 2009;8(4):393–7.

    Article  PubMed  Google Scholar 

  15. Ho MM, Ng AV, Lam S, Hung JY. Side population in human lung cancer cell lines and tumors is enriched with stem-like cancer cells. Cancer Res. 2007;67:4827–33.

    Article  PubMed  CAS  Google Scholar 

  16. Eramo A, Lotti F, Sette G, Pilozzi E, Biffoni M, Di Virgilio A, et al. Identification and expansion of the tumorigenic lung cancer stem cell population. Cell Death Differ. 2008;15:504–14.

    Article  PubMed  CAS  Google Scholar 

  17. Chen YC, Hsu HS, Chen YW, Tsai TH, How CK, Wang CY, et al. Oct-4 expression maintained cancer stem-like properties in lung cancer-derived CD133-positive cells. PLoS ONE. 2008;3:e2637.

    Article  PubMed  Google Scholar 

  18. Eyler CE, Rich JN. Survival of the fittest: cancer stem cells in therapeutic resistance and angiogenesis. J Clin Oncol. 2008;26:2839–45.

    Article  PubMed  CAS  Google Scholar 

  19. Ferrara N, Kerbel RS. Angiogenesis as a therapeutic target. Nature. 2005;438:967–74.

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgments

The work was supported by the Natural Science Foundation of Zhejiang Province, China (No. 2006C13021) and the National Basic Research Program of China (No. 2010CB944901).

Author information

Authors and Affiliations

  1. Respiratory Department, Sir Run Run Shaw Hospital, Affiliated with School of Medicine, Zhejiang University, 3 East Qingchun Road, Hangzhou, 310016, China

    Feng Li & Kejing Ying

  2. School of Life Sciences and Technology, Tongji University, Shanghai, 200092, China

    Huazong Zeng

  3. Tuberculosis Department, The Red Cross Hospital in Hangzhou, 208 East Road, Hangzhou Ring, Hangzhou, 310003, China

    Feng Li

Authors
  1. Feng Li
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Huazong Zeng
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Kejing Ying
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Kejing Ying.

Additional information

Feng Li and Huazong Zeng contributed equally to this work.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Li, F., Zeng, H. & Ying, K. The combination of stem cell markers CD133 and ABCG2 predicts relapse in stage I non-small cell lung carcinomas. Med Oncol 28, 1458–1462 (2011). https://doi.org/10.1007/s12032-010-9646-5

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12032-010-9646-5

Keywords

Search

Navigation